dbo:abstract
|
- Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. The most common side effects include rash, infusion-related reactions, skin infections around the fingernails or toenails, muscle and joint pain, shortness of breath, nausea, fatigue, swelling in the lower legs or hands or face, sores in the mouth, cough, constipation, vomiting and changes in certain blood tests. Amivantamab is a bispecific epidermal growth factor (EGF) receptor-directed and mesenchymal–epithelial transition (MET) receptor-directed antibody. It is the first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Amivantamab was approved for medical use in the United States in May 2021, and in the European Union in December 2021. (en)
- Amivantamab ist ein monoklonaler Antikörper, der als Arzneistoff zur Behandlung bestimmter Formen des nicht-kleinzelligen Lungenkrebses (NSCLC) eingesetzt wird. Für dieses Anwendungsgebiet erhielt er in den USA im Mai 2021, in der EU im Dezember 2021, unter dem Namen Rybrevant (Janssen Biotech) die Zulassung. (de)
- Амивантамаб — лекарственный препарат, противоопухолевое моноклональное антитело для лечения рака легких. Одобрен для применения: США (2021). (ru)
|
dbo:alternativeName
| |
dbo:casNumber
| |
dbo:class
| |
dbo:drugbank
| |
dbo:fdaUniiCode
| |
dbo:kegg
| |
dbo:wikiPageExternalLink
| |
dbo:wikiPageID
| |
dbo:wikiPageLength
|
- 16830 (xsd:nonNegativeInteger)
|
dbo:wikiPageRevisionID
| |
dbo:wikiPageWikiLink
| |
dbp:atcPrefix
| |
dbp:atcSuffix
| |
dbp:c
| |
dbp:casNumber
| |
dbp:class
| |
dbp:dailymedid
| |
dbp:drugbank
| |
dbp:h
| |
dbp:kegg
| |
dbp:legalCa
| |
dbp:legalCaComment
| |
dbp:legalEu
| |
dbp:legalUs
| |
dbp:mabType
| |
dbp:n
| |
dbp:o
| |
dbp:routesOfAdministration
| |
dbp:s
| |
dbp:source
| |
dbp:synonyms
|
- JNJ-61186372, amivantamab-vmjw (en)
|
dbp:target
|
- Epidermal growth factor receptor and Mesenchymal–epithelial transition (en)
|
dbp:tradename
| |
dbp:type
| |
dbp:unii
| |
dbp:wikiPageUsesTemplate
| |
dcterms:subject
| |
rdf:type
| |
rdfs:comment
|
- Amivantamab ist ein monoklonaler Antikörper, der als Arzneistoff zur Behandlung bestimmter Formen des nicht-kleinzelligen Lungenkrebses (NSCLC) eingesetzt wird. Für dieses Anwendungsgebiet erhielt er in den USA im Mai 2021, in der EU im Dezember 2021, unter dem Namen Rybrevant (Janssen Biotech) die Zulassung. (de)
- Амивантамаб — лекарственный препарат, противоопухолевое моноклональное антитело для лечения рака легких. Одобрен для применения: США (2021). (ru)
- Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. The most common side effects include rash, infusion-related reactions, skin infections around the fingernails or toenails, muscle and joint pain, shortness of breath, nausea, fatigue, swelling in the lower legs or hands or face, sores in the mouth, cough, constipation, vomiting and changes in certain blood tests. Amivantamab was approved for medical use in the United States in May 2021, and in the European Union in December 2021. (en)
|
rdfs:label
|
- Amivantamab (en)
- Amivantamab (de)
- Амивантамаб (ru)
|
owl:sameAs
| |
prov:wasDerivedFrom
| |
foaf:isPrimaryTopicOf
| |
is dbo:product
of | |
is dbo:wikiPageRedirects
of | |
is dbo:wikiPageWikiLink
of | |
is foaf:primaryTopic
of | |